Product Information
TRIJARDY XR 12.5-2.5-1,000 MG is a brand product labeled by Boehringer Ingelheim Pharmaceuticals Inc., priced at $5.6255 per EA under NDC 00597038577. Its NADAC has been published 292 times since Jan 20, 2021.
FDA first approved this application on Jan 27, 2020.
Strength
12.5; 2.5; 1000 mg/1; mg/1; mg/1
Manufacturer
Boehringer Ingelheim Pharmaceuticals Inc.NDC
00597038577
Classification
Brand
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA212614FDA Approved
1/27/2020
On Market Since
4/23/2020
Pharmacological Classes
Price Statistics
The NADAC for TRIJARDY XR 12.5-2.5-1,000 MG has been published 292 times since Jan 20, 2021, and over the history we have for it it has declined 35.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.6255 per EA |
|---|---|
| All-time high | $10.1053 (Oct 15, 2025) |
| All-time low | $5.6189 (Jan 7, 2026) |
| 52-week high | $10.1053 |
| 52-week low | $5.6189 |
| Median price | $9.5133 |
| Average price | $9.0416 |
| Largest weekly change | -44.4% (Jan 7, 2026) |
| Weeks tracked | 292 |
| Tracking since | Jan 20, 2021 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of TRIJARDY XR 12.5-2.5-1,000 MG?
The current National Average Drug Acquisition Cost (NADAC) for TRIJARDY XR 12.5-2.5-1,000 MG, manufactured by Boehringer Ingelheim Pharmaceuticals Inc., is $5.6255 per EA (NDC 00597038577), effective Aug 19, 2026.
How has the price of TRIJARDY XR 12.5-2.5-1,000 MG changed over time?
Over the history we have for it, the NADAC for TRIJARDY XR 12.5-2.5-1,000 MG has declined 35.9%. It has been tracked across 292 weekly CMS publications since Jan 20, 2021.
What are the highest and lowest recorded NADAC prices for TRIJARDY XR 12.5-2.5-1,000 MG?
Since Jan 20, 2021, the NADAC for TRIJARDY XR 12.5-2.5-1,000 MG has ranged from a low of $5.6189 (Jan 7, 2026) to a high of $10.1053 (Oct 15, 2025), with a median of $9.5133 per EA.
Are there cheaper alternatives to TRIJARDY XR 12.5-2.5-1,000 MG?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as TRIJARDY XR 12.5-2.5-1,000 MG in a comparable dosage form, but none are currently priced below it.
Who manufactures TRIJARDY XR 12.5-2.5-1,000 MG?
TRIJARDY XR 12.5-2.5-1,000 MG (NDC 00597038577) is labeled by Boehringer Ingelheim Pharmaceuticals Inc., and CMS classifies it as a brand product.